Neoadjuvant chemoteraphy in unresectable ovarian cancer with olaparib and weekly carboplatin plus paclitaxel: a phase II, open label multicenter study (NUVOLA trial)

Claudia Marchetti; Riccardo Tudisco; Vanda Salutari; Antonella Pietragalla; Giovanni Scambia; Anna Fagotti

doi:10.1136/ijgc-2021-002727

Citation Tools

other Versions

You are currently viewing an earlier version of this article (January 08, 2022).
View the most recent version of this article

Clinical trial

Neoadjuvant chemoteraphy in unresectable ovarian cancer with olaparib and weekly carboplatin plus paclitaxel: a phase II, open label multicenter study (NUVOLA trial)

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

BibTeX
Bookends
EasyBib
EndNote (tagged)
EndNote 8 (xml)
Medlars
Mendeley
Papers
RefWorks Tagged
Ref Manager
RIS
Zotero

Cite this article as:: Marchetti C, Tudisco R, Salutari V, et al

Neoadjuvant chemoteraphy in unresectable ovarian cancer with olaparib and weekly carboplatin plus paclitaxel: a phase II, open label multicenter study (NUVOLA trial)

International Journal of Gynecologic Cancer Published Online First: 15 June 2021. doi: 10.1136/ijgc-2021-002727

Log in using your username and password

Main menu

Log in using your username and password

You are here

other Versions

Download to a citation manager

Read the full text or download the PDF:

Log in using your username and password